Actively Recruiting
Phase 12 Open-Label Study Evaluating Safety, Pharmacokinetics, and Antitumor Activity of CR-002 in Adults With Advanced or Metastatic Solid Tumors
Led by Crescent Biopharma, Inc. · Updated on 2026-11-02
219
Participants Needed
3
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of CR-002 monotherapy in adult participants with locally advanced or metastatic solid tumors who have limited treatment options. This Phase 12 study aims to find the maximum tolerated dose, optimal biological dose, and recommended Phase 2 doses of CR-002. The trial includes participants with several types of advanced cancers who are progressing despite or unable to receive standard treatments. The trial consists of multiple parts Part 1 involves stepwise dose escalation in participants with selected advanced solid tumors to find safe dose levels. Part 2 enrolls additional participants at dose levels previously cleared for safety. Potential further cohorts may be added for dose optimization and expansion based on emerging data. CR-002 is given by intravenous infusion during the treatment period. Participants undergo screening to confirm eligibility, followed by treatment with CR-002 and clinical safety assessments including disease scans and blood tests. After treatment, disease scans continue until disease progression. Long-term follow-up occurs every 3 months by telephone. Researchers monitor adverse events, dose-limiting toxicities, pharmacokinetics, and multiple measures of tumor response and survival over up to approximately 36 months.
CONDITIONS
Brief Title
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Research Team
C
Crescent Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here